Podcasts about research funding

Between budget battles, proposed grant rule changes, and an exploding Blue Origin rocket, there's a lot to cover in U.S. space policy right now. Jack Kiraly, The Planetary Society's director of government relations, joins host Sarah Al-Ahmed to walk through a cascade of developments affecting NASA and the broader U.S. science community, including a proposed rule change at the Office of Management and Budget that would hand control of federal research grant decisions to political appointees, bypassing the peer review process that has underpinned U.S. science for decades. Kiraly also discusses a major reorganization at NASA, a new competition for the management of the Jet Propulsion Laboratory, the fallout from the New Glenn explosion, and what it means for the future of Artemis. Plus, in What's Up, the names of the Artemis III crew are revealed. Discover more at: https://www.planetary.org/planetary-radio/2026-us-space-science-in-fluxSee omnystudio.com/listener for privacy information.

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about a link between higher meat and slower cognitive decline in APOE34/44 carriers, the geographic distribution of research funding, and how artificial intelligence is reshaping neurology.

Summary: Hidradenitis Suppurativa (HS) is one of dermatology's most complex and underrecognized conditions and the treatment landscape is changing fast. In this episode, Dr. Faranak Kamangar sits down with Dr. Hadar Lev-tov, Associate Professor at the University of Miami, Director of the Wound Healing Fellowship, and Immediate Past President of the Hidradenitis Suppurativa Foundation, for a rapid-fire review of everything happening in the HS world right now. Dr. Lev-tov covers the currently approved therapies, the exciting drugs moving through Phase 3 trials, and the groundbreaking science linking microplastics to HS inflammation. He also shares his candid take on GLP-1s in HS management and what the future of dermatology looks like when treatments work so well that doctors can finally focus on the whole patient. Whether you're a resident just learning HS or a seasoned dermatologist trying to keep up with a fire-hose pipeline, this one is for you. Topics Covered: - Approved HS biologics: bimekizumab, secukinumab, adalimumab & biosimilars - Off-label use of infliximab (IV and subcutaneous) in severe HS - Phase 3 pipeline: remibrutinib, povorcitinib, sonelokimab (nanobodies) - CAR T-cell therapy and the possibility of curing inflammatory skin disease - Microplastics, nicastrin, and a landmark Nature Communications paper on HS - GLP-1s in HS: what we know, what we don't, and Dr. Levtov's clinical approach - The HS Foundation's research grants, HS Academy, wound care referral tool, and prior authorization templates - The future of dermatology as lifestyle medicine Resources Mentioned: - https://www.nature.com/articles/s41467-025-65789-7  - HS Foundation website & prior authorization templates: https://www.hs-foundation.org/ - HS Academy (free weekend for residents): https://www.hs-foundation.org/hs-academy - Integrative Dermatology Symposium: integrativedermatologysymposium.com - LearnSkin: learnskin.com This podcast is for educational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider. Key Takeaways: 1. Validate HS patients the moment they walk in. They've often been dismissed or bounced between providers for years. Simply saying "I understand what you're going through" builds trust immediately and makes the visit more productive. 2. The approved HS treatment arsenal is growing. Bimekizumab and secukinumab (IL-17 inhibitors) are now approved, and adalimumab — including biosimilars — remains a valuable option. Clinical experts are using biosimilars with confidence. 3. Subcutaneous infliximab is an emerging option. Available off-label in the US, new data from French centers shows a protocol: standard IV induction at weeks 0, 2, and 6, then switching to subcutaneous injections every two weeks at week 10 — but only once the patient is in strong remission. 4. Three major drugs are in or completing Phase 3 trials. Remibrutinib (BTK inhibitor, already approved for chronic spontaneous urticaria), povorcitinib (JAK1 inhibitor), and sonelokimab (a nanobody targeting IL-17A and IL-17F) are all reporting promising results and moving toward FDA application. 5. Nanobodies are a technology to watch. Derived from camelid antibody fragments, nanobodies like sonelokimab can be engineered to target multiple pathways simultaneously in a smaller, more modular molecule — expect to see them across dermatology. 6. Half-life extenders could mean one injection per year. Already emerging in psoriasis, these extended-dosing biologics are heading toward HS — a potential game-changer for patient adherence. 7. CAR T-cell therapy may one day cure inflammatory skin disease. Currently being studied in lupus and rheumatoid arthritis, the protocols are becoming more practical, and the technology is edging toward dermatology. 8. Microplastics may potentiate HS inflammation. A Nature Communications paper by Dr. Luis Garza (Hopkins) found that plastic-associated endocrine disruptors block nicastrin in fibroblasts, amplifying HS-related inflammation. This doesn't prove causation, but it reveals a meaningful environmental link — and highlights the underappreciated role of fibroblasts in HS scarring. 9. GLP-1s in HS: promising but not proven as monotherapy. There's no RCT yet. Dr. Levtov's clinical approach: stabilize HS with a biologic first, then consider adding a GLP-1 as part of a comprehensive plan that includes diet and resistance training. He has seen outcomes go both ways. 10. The HS Foundation is an underutilized resource. Their website offers a clinic finder, wound care referral service, prior authorization templates (one-click Word documents), research grants, the HS Academy (free, all-expenses-paid weekend for residents), and career development awards in partnership with the Dermatology Foundation. Chapters: 0:00 – Introduction & Dr. Lev-tov's Background 0:49 – The #1 Clinical Tip for Seeing HS Patients 1:44 – Approved HS Treatments: IL-17 Inhibitors, Adalimumab & Biosimilars 2:40 – Off-Label Infliximab: IV and the New Subcutaneous Protocol 4:21 – Phase 3 Pipeline: Remibrutinib, Povorcitinib & Sonelokimab (Nanobodies) 6:00 – Half-Life Extenders & One-Injection-Per-Year Future 7:01 – CAR T-Cell Therapy: Could We Cure Inflammatory Skin Disease? 7:36 – Research Funding & HS Foundation Grants 8:43 – HS Foundation Tools: Prior Auth Templates, Clinic Finder & HS Academy 10:15 – Microplastics, Nicastrin & the Nature Communications Paper 13:22 – What This Means for Fibroblasts and HS Scarring 14:20 – Celebrating Dermatology Science & Clinician-Scientists 15:32 – GLP-1s & HS: What's the Evidence? 17:18 – Dr. Lev-tov's Clinical Approach to GLP-1 Requests 19:06 – The Future of Dermatology: Becoming Lifestyle Doctors 21:28 – The Integrative Dermatology Symposium & LearnSkin Certificate Program 22:50 – Closing Remarks

Australia lags behind most OECD countries when it comes to percentage of GDP spent on scientific research. Belinda Smith speaks to scientists impacted with a response from science minister Tim Ayres.

The Georgia Peanut Commission board of directors has approved over $764,000 in research project funding for 2025-26, and the FAA is accelerating enforcement of drone regulations, a move that could have broad implications for farmers.

In Episode 129, we explain why floor crossings are constitutionally permitted in Parliament even if they betray local voters, and we dig into the Canada Research Chair program's quotas, which lead to professor job postings limited to only women and people with disabilities.Stories and cases discussed in this week's episode:2019 Addendum to the 2006 Canadian Human Rights Settlement Agreement (Canada Research Chairs)2021 Canadian Human Rights Settlement Agreement (Canada Research Chairs)Assistant or Associate Professor- Tier 2 Canada Research Chair in Forestry and Environmental Stewardship (UBC)Could we ban floor crossing in Canada (Brian Lilley)Preston Manning: It is time for some Liberals to cross the floor (National Post)Not Reserving Judgment is a podcast about Canadian constitutional law hosted by Josh Dehaas, Joanna Baron, and Christine Van Geyn, with help from Alexander Surgenor.The show is brought to you by the Canadian Constitution Foundation, a non-partisan legal charity dedicated to defending rights and freedoms. To support our work, visit theccf.ca/donate.

A bipartisan group of senators is pushing to boost research funding for Historically Black Colleges and Universities. The proposed legislation would streamline access to federal grants and create new opportunities for STEM innovation at HBCUs. Subscribe to our newsletter to stay informed with the latest news from a leading Black-owned & controlled media company: https://aurn.com/newsletter Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What happens when scientists are right and nobody wants to hear it? Neil deGrasse Tyson, Chuck Nice, and Gary O'Reilly explore the frustrating history of brilliant minds who were ignored, mocked, and punished for telling the truth with science writer Matt Kaplan. NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free here:  https://startalkmedia.com/show/told-you-so-with-matt-kaplan/ Thanks to our Patrons William D A, JK Smith, k c, Jim Worke, ufuk mevlevioglu, discount, Mark Snow, scott.hraha@gmail . con, Daren Covington, alex fricke, Alistair Gray, Jordi Estevez, Jeppe Blomgren, Kal McCloud, James Hale, Olivia Ruffe, Barbara, Tyler Dirkse, Bupkis Null, Tamajai Parrotte, Ebony Davis, Hailey Drake, Josh Whalen, SomethingWonderful, Ms.Yi, Luke Williams, L M, DP, Noah Golden, Courtney Minick, Megs, Jake, Terry Kirk, Joe G, Kip Kerley, Alec Walters, Alex Brown, Baxter, Austin Garcia, Sam W, Ladie Charette, Patrick Laverdière, juno brown, John Gary, Lucidious Flow, Leticia Farrar, Chu88, Fatima, Adrienne Bennett, David Labas, David Presnell, BLUE TIGER, Theresa Anoskey, Jahkenan Lloyd, Sambath Kumar Balasubramanian, Michelle Hester, Tatjana Gall, bandofspartans, Scarlet_Bukur92, LeopaldChaos, Mark Schwerin, Jack, Andrew, Edward Landry, Roland, Daniel Peter, Dan, Derek C, Erik Mardiste, Samuel Young, Keith McCredie, Dom, Ulq, Israel Soto, Q/Aurora Phoenix, JeanieZee, Terry Carr, Todd Bergmann, meteor guy, Patrick Congdon, Jeremiah Lewis, Janet Staples-Edwards, Eric Mensah, Chris Morales, Timothy Stanford, Dean Lasseter, Daniel Hays, Madhur Behl, Professor Grumbly Gut, Max Wolters, Jeremy Lewis, José Ikamba, Ian Ravenshaw Bland, Ron Spee, Brandon Smith, Richard Lord, Cody Avery Campbell (codesuniverse), Shawn Shields, M.R. Saar, and Nicole Elizabeth for supporting us this week. Subscribe to SiriusXM Podcasts+ to listen to new episodes of StarTalk Radio ad-free and a whole week early.Start a free trial now on Apple Podcasts or by visiting siriusxm.com/podcastsplus. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Flex Diet Podcast, I sit down with Dr. Ashley Dwyer, a PharmD-turned nutrition and fitness coach, to cover a wide range of topics, with a strong focus on PCOS (polycystic ovarian syndrome), a metabolic condition that affects fertility, cycles, and systemic health.  We dig into practical lifestyle strategies for insulin-resistant PCOS, including balanced meals, protein and fiber, blood sugar management, movement, and stress reduction, plus why long-term keto often isn't a great fit. We also discuss GLP-1 medications, including concerns about HRV and resting heart rate, and why foundations and coaching matter when someone uses them.  Finally, we discuss the current “wild west” of peptides, the lack of human data, dosing and purity issues, and the importance of transparency, consistency, and identity-based behavior change for body composition and long-term health. Sponsors: Flex4: Dr Ashley Dwyer's top 4 things for women to improve body composition: https://miketnelson.com/flex4 Daily Fitness Insider Newsletter: https://flex-diet.kit.com/bfa1510fa8 Check out: Real Coaches Summit 2026: https://realcoachessummit.com Available now: Grab a copy of the Triphasic Training II book I co-wrote with Cal Deitz here. Episode Chapters: 05:02 Meet Dr Ashley 06:16 PCOS Explained 09:37 PCOS Nutrition Basics 11:31 Keto And Thyroid 15:21 Stress And Cardio 18:27 GLP1 Heart Effects 22:21 Maintenance And Habits 30:27 Identity And Mindset 32:56 Identity Reps and Habits 33:25 Daily Affirmations and Reminders 34:23 Taming Negative Self Talk 36:24 Peptides Hype and Risks 38:18 Anecdotes Dosing and Quality 42:38 Influencers Quick Fixes Foundations 43:56 Research Funding and Regulation 47:40 Transparency Natty vs Enhanced 49:55 Coaching Clients on Supplements 56:20 Outro Summit and Disclaimers Flex Diet Podcasts you may enjoy: Episode 359: Debunking Women's Fitness Myths with Dr. Lauren Colenso-Semple YouTube: https://www.youtube.com/watch?v=AG_iahp6t40 Episode 292: Expert Insights on Pelvic Floor Health, Stress Management & Functional Technique with Dr Catrina Fabian YouTube: https://www.youtube.com/watch?v=J3V3tCse-IA Connect with Dr Dwyer: Instagram: https://www.instagram.com/dr.dwyer Get In Touch with Dr Mike: Instagram: Drmiketnelson YouTube: @flexdietcert Email: Miketnelson.com/contact-us

Sexual medicine is underfunded, misunderstood, and often dismissed. But it's also one of the most collaborative fields in healthcare. Dr. Tami Rowen recaps this year's ISSWSH conference and what it revealed about where the field is heading.Dr. Rowen is the current president elect of ISSWSH and has been instrumental in shaping sexual medicine education and research. We recorded this right after the 2026 ISSWSH conference in Long Beach, which had almost 600 attendeesone of our biggest conferences yet.We discuss the standout research from the meeting, including award winning work on sexual function after gender-affirming hysterectomy and why most top abstracts focused on sexual pleasure rather than prevention. We talk about the reality of research funding in sexual medicine, why industry support creates conflicts of interest that look bigger than they are, and how lack of NIH funding means we have almost no treatment options for conditions like vulvodynia.We also dive into testosterone therapy why it's controversial, what the data actually shows versus what social media claims, and why Dr. Rowen doesn't treat hormone levels but rather treats individuals with specific goals. We discuss body image after breast cancer surgery, lymphedema's impact on sexual function, and why technoference is contributing to the lowest rates of sex we've ever seen.HighlightsISSWSH focuses on sexual pleasure and quality of life, not just prevention of pregnancy and STIs.Research funding for vulvodynia is $4 million annually versus $800 million for breast cancerthat's one grant versus hundreds.Testosterone therapy should treat symptoms and goals, not hormone levels or deficiencies.Body image and sexual function outcomes are significantly worse after mastectomy versus lumpectomy, even though cancer outcomes are equal.Technoference (technology interference) is contributing to historically low rates of sexual activity.If you're a clinician interested in sexual medicine, consider attending the ISSWSH Fall Course for foundational education and the annual meeting for cutting-edge research. If you're a patient navigating any issues and not currently getting help, know that there are practitioners out there who want to help you.Subscribe to the podcast and share this episode with anyone who wants to learn more about sexual medicine, menopause, or women's health education.Get in Touch with Dr. RowenWebsiteInstagramGet in Touch with Me: WebsiteInstagramYoutubeSubstackMentioned in this episode:GSM CollectiveThe GSM Collective - Chicago Boutique concierge gynecology practice Led by Dr. Sameena Rahman, specialist in sexual medicine & menopause Unrushed appointments in a beautiful, private setting Personalized care for women's health, hormones, and pelvic floor issues Multiple membership options available Ready for personalized women's healthcare? Visit our Chicago office today. GSM Collective

The City Bar's Presidential Task Force on AI and Digital Technologies hosts today's podcast on President Trump's:  Winning the Race, America's AI Action Plan. Task Force co-chair Jerome Walker is joined by task force members Matthew Bacal (Davis Polk), Azish Filabi (American College of Financial Services), Robert Mahari (Stanford Codex), and Evan Abrams (Steptoe), to review the plan's three pillars and key action steps. Pillar One (“Accelerate AI Innovation”) is described as largely deregulatory, including agency review of rules and certain FTC/FCC actions, with targeted concerns such as ideological bias and synthetic media in the legal system, plus investments in open-source/open-weight models, data, interpretability, evaluations, and government/DoD adoption. Pillar Two (“Build American AI Infrastructure”) focuses on the physical side of AI—permitting for data centers and fabs, energy and grid expansion, semiconductors, water for cooling, workforce training, cybersecurity, and “security by design,” while anticipating trade-offs and litigation. Pillar Three (“Lead in International AI Diplomacy and Security”) balances support for exporting US “full stack” AI with tighter national security controls, including stronger export-control enforcement and participation in international bodies primarily to counter China. The conversation closes with suggestions for improving the plan by strengthening trust, safety/rights considerations, and maintaining flexibility as AI capabilities evolve. If you are interested in learning more about emerging AI developments and policy, join us for the 2026 Artificial Intelligence Conference on June 18 to hear from industry experts and connect with leading legal professionals across the field. 00:00 Trump's 2025 AI Action Plan: Big Goals, Short Document, 3 Pillars 03:23 Pillar One Preview: 15 Action Steps to ‘Accelerate AI Innovation' 09:16 Meet the Panel + Setting Up the Pillar One Deep Dive 11:21 Pillar One Explained: Deregulation, Free Speech, Data Sharing, Evaluations, and Trust 18:33 Key Takeaways for Stakeholders: Business, Finance, Civil Society, and Tech 23:57 Which Pillar One Steps Matter Most? Sequencing, Competitiveness, and Data Access 27:52 Pillar Two: The Physical Side of AI—Energy, Chips, Data Centers 36:32 Critical Infrastructure Security: Physical Risks, Cyber Threats & ‘Security by Design' 37:14 Data Poisoning Explained: How Training Data Can Be Manipulated at Scale 38:00 Workforce Training at Scale: From Trades to Semiconductor Talent Pipelines 38:52 Wrapping Pillar Two: China Competition, Speeding Projects, and Ranking Priorities 40:34 What Lawyers & Judges Need to Know About Pillar Two (Red Tape, Legal Tech, Litigation) 45:30 Pillar Three Overview: Balancing Global AI Leadership with National Security Controls 50:05 Pillar Three Priorities by Industry: Export Controls, Frontier Evaluations & Data Center Risk 58:56 Why Engage International AI Bodies? Countering China and Filling the Leadership Vacuum 01:03:20 Trump vs. Biden Narratives: Competition vs. Safety—What Should Change in the Plan? 01:07:38 Panel Advice to Improve the Action Plan: Rights Framework, Nimble Policy, Safety & Research Funding

This week on the podcast student finance has exploded into the headlines – but is the English student loan system really doomed? Backbench Labour MPs are pressing the chancellor to act, polling has revealed widespread antipathy for above-inflation interest rates, and Rachel Reeves has clashed with Martin Lewis over the freeze to repayment thresholds. Now former OfS access tsar John Blake has launched The Post-18 Project, our Wonkhe think tank, by arguing that a review of higher education funding is unavoidable and that a graduate tax should be one of the options. So is the government going to act, or will it be bounced into action?Plus UKRI has found itself in a perfect comms storm over the future of curiosity-driven research funding, and Michael Salmon sits down with Welsh minister Vikki Howells to discuss the challenges facing tertiary education.With Ben Ward, CEO at University of Manchester Students' Union, Smita Jamdar, Partner and Head of Education at Shakespeare Martineau, Michael Salmon, News Editor at Wonkhe, Vikki Howells, Minister for Further and Higher Education in the Senedd and presented by Jim Dickinson, Associate Editor at Wonkhe.The Post-18 Project: A review of higher education funding is inevitableFive challenges faced by the Welsh tertiary sectorMaybe a graduate tax wasn't such a bad idea after allWelsh higher education is running out of wriggle roomWales refuses to implement Westminster's stealth graduate tax raidWho should pay for our failing student loan system?

Questions about the future of federal TRIO programs—academic and support services for low-income, first-generation, and disabled students—come up more than almost any other topic on the podcast. We're joined this week by Kimberly Jones, president of the Council for Opportunity in Education, for a conversation about where TRIO stands and what may be ahead. We begin with some speculation on whether or not we're heading toward a partial government shutdown, and the latest on the Department of Education's moves on accreditation. Here are some of the links and references from this week's show: Contact Congress to Urge a Broader Professional Degree Definition 2026 Winter Term Pulse Point Survey (PDF) Appropriations House Passes FY 2026 Spending Package Preserving Education and Research Funding as Senate Showdown Looms  ACE | Jan. 26, 2026 ACE, Higher Ed Groups Urge Congress to Safeguard FY 2026 Education Funding  ACE | Oct. 1, 2025 Letter to Congress on MSI Funding  ACE | Oct. 3, 2025 Legal Updates Education Dept. Drops Appeal of Court Order Blocking Anti-DEI Guidance  Inside Higher Ed | Jan. 22, 2026 Higher Ed Groups Back Harvard in Appeal Challenging Trump Proclamation on International Students  ACE | Jan. 21, 2026 Accreditation U.S. Department of Education Announces Negotiated Rulemaking to Reform and Strengthen America's Higher Education Accreditation System  Department of Education | Jan. 26, 2026 ED Eyes Rewrite of Accreditation Rules  Inside Higher Ed | Jan. 27, 2026 Comments on the Education Department's Proposed Revisions to the Accreditation Handbook ACE | Jan. 26, 2026 NACIQI Members Stalemate on Picking New Chair Republic Report (December 2025) TRIO Council for Opportunity in Education and TRIO Programs COE Trio Advocacy Congressional Outreach Packet Federal Court Orders Reconsideration of Canceled TRIO Grants Inside Higher Ed | Jan . 20, 2026 Trump's DEI Crackdown Closes 120 TRIO Programs Inside Higher Ed | Oct. 27, 2025 Trump Administration Delays $660M for College Access Programs  Inside Higher Ed | Sept. 12 2025

Hosts Tod Ibrahim and Lauren Ahearn are joined by Rachel Meyer, ASN Senior Strategic Policy Advisor to the EVP, to break down where things stand on federal appropriations, kidney health research funding, and what to expect as we head into 2026.

Hosts Tod Ibrahim and Lauren Ahearn are joined by Rachel Meyer, ASN Senior Strategic Policy Advisor to the EVP, to break down where things stand on federal appropriations, kidney health research funding, and what to expect as we head into 2026.

A well known scientist says she's out of options for funding her research as it gets even tougher to get grants or donations. PHD students are also facing an up hill battle. Award wininng microbiologist Siouxsie Wiles has been turned down for four grants for her research into the safety of resusable menstrual cups. She says when economic times are tough, money for research dries up and funding decisions tend to get more conservative. University of Auckland Associate Professor Siouxsie Wiles spoke to Lisa Owen.

In this timely episode, hosts Val and Dana break down what's shifting in pediatric cancer research funding, and why it matters for kids right now. As a follow-up to an earlier episode about federal funding in 2026, we unpack details on the appalling federal funding cuts planned for pediatric cancer research.In this episode we see:What a projected 37% cut to NCI's budget could mean for pediatric research (fewer grants, center consolidations, and mid-stream project disruptions).Why “More than Four” still matters, and how 4% of NCI funds for pediatrics has always fallen short.The latest on the Childhood Cancer Data Initiative (CCDI), including the executive order matching $50M (bringing CCDI to $100M for the year) and how data + AI can accelerate precision options for kids.Potential impacts to programs like the Pediatric Brain Tumor Consortium, Pediatric Early Phase Clinical Trials Network, intramural high-risk research, and training awards for emerging scientists.On-the-ground advocacy updates from Capitol Hill, and the power of survivor voices leading the charge.Bright spots in Florida's state investments in cancer research infrastructure, and why long-term, consistent funding is still essential.If you'd like to read more:Recap the facts from this conversation in our blog on federal funding cuts.Review the NCI's report directly by clicking this link.If this conversation moves you, please like, comment, and share to help us educate for change. Leaving a review helps more families find tangible hope.Tune in to hear this inspiring and informative conversation. Don't forget to subscribe, leave a review, and join the fight to make Game Over: c*ncer a reality.Connect with Dana: https://www.linkedin.com/in/danaknichols/Connect with Val: https://www.linkedin.com/in/valerie-solomon/Upcoming Ckc Events: https://cannonballkidscancer.org/category/make-an-impact/events/----------------------------------Podcast Produced by Hi Hello Labs: Website: https://www.hihellolabs.com/

What happens when a powerhouse research enterprise, a statewide health system, and a relentless push for access all meet at the same table? Our conversation with Dr. David Miller, CEO of Michigan Medicine, opens the door to a candid look at how precision care, digital tools, and financial reality collide—and how smart leadership turns that collision into progress.We dig into the new map of Michigan Medicine: the academic medical center in Ann Arbor, integrated hospitals in Lansing and West Michigan, and partnerships that extend specialty expertise across the state. Then we follow the research-to-care pipeline, from NIH-backed labs to clinical trials to real-world therapies. You'll hear how next-generation sequencing is making targeted cancer treatments more accessible, and why histotripsy—a noninvasive, ultrasound-based approach to treating liver tumors—is a model for bringing breakthroughs from engineering benches to exam rooms.Technology is more than a buzzword here. Dr. Miller explains how generative AI is cutting documentation time with ambient notes, speeding routine approvals, and supporting clinical decisions, all while keeping a human in the loop. We talk training the next wave of physicians to be technology fluent, and how virtual visits and remote monitoring expand access without trading away empathy. On payment and policy, we confront the hard parts: Medicaid churn, prior authorization friction, and the need for value-based insurance design that lowers barriers to high-value care. The throughline is simple and urgent—make it easier for patients to get the right care at the right time, and align incentives so innovation actually reaches people.If you care about healthcare that is precise, humane, and actually reachable, this conversation will give you a practical, hopeful blueprint. Subscribe, share with a friend who's navigating care, and leave a review to help more listeners find the show. Your feedback keeps this community sharp—and pushes the system toward what works.Support the showEngage the conversation on Substack at The Common Bridge!

Behind every medical breakthrough for kids is usually a long history of research advances. Research is incremental, and new therapies exist, thanks to questions that are asked in science laboratories. Those investigators not only asked the hard questions but also found the funding to answer them. What happens when that funding starts to disappear? Research drives progress in pediatric medicine from vaccines to breakthrough treatments for rare diseases. That progress is currently at risk. Cuts and cancellations in key federal research programs, including CDC and NIH funding, threaten to stall discoveries and disproportionately impact pediatric investigators. In this episode, we dig into what's happening with child health research funding, why it matters for every pediatrician, and where the greatest opportunities for advocacy lie. For this episode, we are joined by two experts at the forefront of this conversation. Joe St. Geme, MD, is the Physician in Chief at the Children's Hospital of Philadelphia, as well as the President of the CHOP Practice Association. He is also a professor at the University of Pennsylvania Perelman School of Medicine. Zach Zaslow is the Vice President of Advocacy and Community Health at Children's Hospital Colorado. Some highlights from this episode include:  The status of pediatric research funding  How pediatric research directly impacts community pediatricians  What current threats exist  How providers can advocate for their patients and families   For more information on Children's Colorado, visit: childrenscolorado.org. 

On our 300th episode, former Secretary of State Condoleezza Rice talks about her return to Stanford after years in government and the impact she sees rapidly advancing technologies having on democracy and public policy. She says the future demands greater collaboration among industry, academia, and government to ensure promising fields like quantum computing and AI are used for the greatest good—in education, medicine, and the sciences. We are in a race that we must win, Rice tells host Russ Altman on this special episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Condoleezza RiceConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Condoleezza Rice, former U.S. Secretary of State and a professor of political science and political economy at Stanford University.(00:04:08) Returning to StanfordWhy Condoleezza returned to academia after serving as Secretary of State.(00:04:50) Higher Education & Public TrustPotential factors impacting universities' connection to the broader public.(00:07:31) Why Research Still MattersThe importance of curiosity-driven, federally funded university research.(00:09:32) Hoover's Emerging Tech InitiativeAn outline of the Hoover Institution's Tech Initiative and its policies.(00:12:11) Uniting Scientists & PolicymakersHow engineers and researchers are engaging with policy and ethics.(00:13:41) The Race For InnovationEmerging themes and key enablers in the technology innovation race.(00:19:17) Industry in the LeadHow private companies are now the primary drivers of innovation.(00:22:02) Global Tech & National InterestsThe tension between globalized tech firms and U.S. policy interests(00:24:35) AI & EducationUsing AI as a tool to enhance teaching and critical thinking in students.(00:28:30) Students Driving PolicyThe contribution students are making to Hoover's tech policy work.(00:29:23) Future In a MinuteRapid-fire Q&A: hope, innovation, time, humanity, and alternate careers.(00:31:09) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Longevity by Design, our host, Dr. Gil Blander, sits down with Dylan Livingston, CEO at the Alliance for Longevity Initiatives, and Dr. Brenda Eap to explore how public policy shapes the future of aging research. Dylan and Brendan share how their team pushes for legislation that supports healthy lifespan extension, aiming to bring longevity science into the center of national health priorities.Dylan and Brendan explain why policy advocacy is crucial for securing funding for research, reducing regulatory hurdles, and establishing a clear path for new therapies. They outline recent successes, including building bipartisan support in Congress and expanding access to experimental treatments in states such as Montana. Throughout their discussion, Dylan shows how effective communication,  using stories and simple analogies, helps move longevity from the lab to lawmakers' agendas.The episode closes with practical advice for listeners. Dylan highlights the power of community, clear communication, and grassroots action as tools that help turn advanced science into real-world health gains.Episode highlights:[00:00:00]: Introduction[00:01:00]: Overview of Longevity Policy and Research Funding[00:02:00]: Backgrounds and Personal Journeys into Longevity Advocacy[00:05:00]: Inspiration and Founding of Longevity Policy Organization[00:07:00]: Scientific Training and Motivation for Policy Work[00:09:00]: Mission and Approach of Longevity Advocacy Organization[00:10:00]: Policy Advocacy's Role in Advancing Longevity Research[00:12:00]: Gaps in Funding and the Importance of Government Engagement[00:13:00]: Experiences with Policy Events and Realizations about Advocacy[00:14:00]: Early Accomplishments and Congressional Engagement[00:15:00]: Building Bipartisan Support and the Longevity Science Caucus[00:16:00]: Legislative Engagement and Policy Paper Development[00:17:00]: State-Level Policy Wins and Expansion of Right to Try Laws[00:19:00]: Rationale and Strategy for State-Level Focus[00:21:00]: Plans for Geographic Expansion of Longevity Policy Initiatives[00:23:00]: Political Climate and Opportunities with the Current Administration[00:25:00]: Shifts in Federal Attitudes Toward Longevity and Healthspan[00:27:00]: Demographics, Policy Momentum, and National Health Priorities[00:29:00]: Prevention Versus Treatment: Shifting Policy Mindsets[00:32:00]: Communicating Policy Opportunities to a Wider Audience[00:34:00]: Ensuring Longevity Policy Remains Bipartisan[00:35:00]: Intersection of Policy, Science, and Public Engagement[00:37:00]: Funding and Regulatory Challenges in Longevity Research[00:39:00]: Barriers in Clinical Trials and Policy Modernization[00:40:00]: Strategies for Communicating Longevity Science to Policymakers[00:44:00]: Framing Longevity for Policy Impact and Public Understanding[00:48:00]: Future Vision and Milestones for Longevity Policy[00:51:00]: How Individuals and Organizations Can Support Longevity Advocacy[00:55:00]: Practical Longevity Advice and Episode ConclusionWe Appreciate You!As a token of our gratitude, we're excited to offer you 15% off your next purchase. Simply click the link below to redeem your discount: https://info.insidetracker.com/podcastFor science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast

A federal judge restores hundreds of research grants to UCLA. The DOJ's Civil Rights Division is suing LASD over Second Amendment concerns. Kamasi Washington talks about his residency at the Blue Note L.A., which starts tonight. Plus, more in this Evening Edition of The LA Report. Support The L.A. Report by donating at LAist.com/join and by visiting https://laist.comVisit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency! Support the show: https://laist.com

UC Davis is a powerhouse for breakthroughs and impact. Our interdisciplinary research plays a vital role in building the region's economy. Our research improves the quality of life of residents and contributes to America's global leadership in technology and innovation. Through collaboration between our top-ranked hospital and veterinary school, as well as our science and engineering discoveries, our research directly improves American lives. Series: "UC Davis News" [Science] [Show ID: 41053]

UC Davis is a powerhouse for breakthroughs and impact. Our interdisciplinary research plays a vital role in building the region's economy. Our research improves the quality of life of residents and contributes to America's global leadership in technology and innovation. Through collaboration between our top-ranked hospital and veterinary school, as well as our science and engineering discoveries, our research directly improves American lives. Series: "UC Davis News" [Science] [Show ID: 41053]

Kimberly Peters, a stage four uterine cancer patient at UC San Diego Health, urges government leaders not to cut science funding. She warns that reduced federal support risks delaying vital research and life-saving cures. [Health and Medicine] [Show ID: 41071]

Kimberly Peters, a stage four uterine cancer patient at UC San Diego Health, urges government leaders not to cut science funding. She warns that reduced federal support risks delaying vital research and life-saving cures. [Health and Medicine] [Show ID: 41071]

In the past several months, the Trump administration has frozen, cancelled, or rescinded millions—even billions—of dollars in federal funding for scientific and clinical research. This is funding that flows directly from bodies like the NIH to universities, academic medical centers, and others to facilitate basic science research, translational research, public health initiatives, and more. Frankly, many organizations did not see these cuts coming—at least not at this scale. And the impacts are likely to touch most every corner of the industry. This week, host Abby Burns sits down with Advisory Board experts Emily Heuser and Gaby Marmolejos to dig into how these cuts are being orchestrated and the ripple effects they may cause across—and even beyond—the healthcare industry. We're here to help: Read: How research funding cuts are impacting healthcare (and how to respond) Check out: Healthcare policy updates Check out: Philanthropy Keep track: Healthcare Policy Updates Timeline Use our tool: How policy changes will impact your bottom line Research Membership Grant Witness Navigating healthcare's next frontier: 5 takeaways from the CHG Healthcare Executive Summit A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

Jay from AxonDAO breaks down decentralized science in plain English: giving people ownership of health data, enabling ethical AI insights, and funding research via a governed community. We cover live use cases like A+Voice (voice biomarkers for early Alzheimer's/dementia signals) and CureRING+CureOS (a data vault + wearable), plus how AxonDAO supports external researchers and projects (e.g., LymeDAO). Jay also shares a sharp playbook for storytelling, positioning, and growth in frontier tech—who to learn from, what to avoid, and how to keep product, narrative, and feedback loops tight.Key Timestamps[00:00:00] Intro — science x AI x Web3 [00:01:05] Jay's path: SA banking → security → tech → crypto[00:02:40] What AxonDAO is (and isn't): DeSci, data ownership, ethical AI, funding [00:03:35] Projects: A+Voice (voice biomarker analysis)[00:04:35] CureRING + CureOS: wearable + personal health data vault [00:05:45] How AxonDAO supports researchers (network, platform, milestone funding) [00:07:05] Why not start with hospitals/gov data? Design partners and product truth [00:08:20] The hard part of marketing DeSci; proving the model [00:09:35] Explaining DeSci to family: “the commons for science” [00:10:45] Selecting projects: societal value, acceleration potential, founder grit [00:12:05] Storytelling that converts: category, positioning, emotional resonance [00:13:20] Shout-outs: Myosin's Simon Yi; Celestia's Ekram Ahmed; BioProtocol [00:14:40] Three growth tips: talk to users; avoid shiny pivots; roadmap with feedback [00:16:50] Host's advice: ask better questions; product > marketing > sales [00:18:10] Vision (2–3 yrs): self-sovereign health data; infra for global researchers [00:20:05] Challenges ahead: crowded wearables; agentic AI UX; controlled growth [00:21:05] The Ask: Series A opening; looking for ML/AI talent; links & contactConnecthttps://www.axondao.io/https://x.com/Axondaohttps://www.linkedin.com/in/jarrod-frankel/https://x.com/jay_franks91DisclaimerNothing mentioned in this podcast is investment advice and please do your own research. Finally, it would mean a lot if you can leave a review of this podcast on Apple Podcasts or Spotify and share this podcast with a friend.Be a guest on the podcast or contact us - https://www.web3pod.xyz/

AP correspondent Haya Panjwani reports on cuts to funding at the nation's health institute.

In this episode of Stanford Legal, host Professor Pamela Karlan interviews her Stanford Law School colleague Professor Lisa Larrimore Ouellette about actions by the Trump administration that Ouellette says are undermining scientific research and jeopardizing America's longstanding global leadership in medicine and innovation. Drawing on an essay she penned for Just Security, Ouellette explains how decades of bipartisan support for federally funded science—an engine of American innovation since World War II—is now at risk. From canceling grants already approved through peer review, to capping essential “indirect cost” reimbursements, she details how these moves threaten not just labs and universities but also patients, whose clinical trials are being abruptly halted.  Ouellette also highlights a second front in her current scholarship: how drug development policy can be better aligned with public health needs. As a member of a National Academies committee, she recently co-authored a report showing that both private investment and federal funding often fail to prioritize diseases causing the greatest suffering. Links:Lisa Larrimore Ouellette >>> Stanford Law pageThe Trump Administration's Multi-Front Assault on Federal Research Funding  >>> Just Security pageStanford Law's Lisa Ouellette Helps Shape New Report on Drug Development Reform  >>> Stanford Lawyer online featureConnect:Episode Transcripts >>> Stanford Legal Podcast WebsiteStanford Legal Podcast >>> LinkedIn PageRich Ford >>>  Twitter/XPam Karlan >>> Stanford Law School PageStanford Law School >>> Twitter/XStanford Lawyer Magazine >>> Twitter/X(00:00) Research Funding (05:01) The Competitive Grant Process (15:01) Addressing Disease Burden (20:00) Impacts of Stopped Clinical Trials (25:01) The Role of Federal Investment in Innovation 

Kennedy said the technology is ineffective, unsafe and unethical. But health officials and researchers are concerned.

Kennedy said the technology is ineffective, unsafe and unethical. But health officials and researchers are concerned.

Over 40 million Americans have been diagnosed with bipolar disorder, and many more go undiagnosed. This episode takes a deep dive into what we know (and don't know) about bipolar I and II, why science has lagged behind, and what a groundbreaking new initiative—BD²: Breakthrough Discoveries for Thriving with Bipolar Disorder—is doing to change that. Host Morra Aarons-Mele speaks with Dr. Mark Frye, psychiatrist and professor of psychiatry at Mayo Clinic in Rochester, Minnesota, Dr. Kate Burdick, Distinguished Chair in Psychiatry and the Vice Chair for Research in Psychiatry at Brigham and Women's Hospital in Boston, MA, and neuroscientist and BD² initiative lead Dr. Cara Altimus about the genetics, biology, and lived experience of bipolar disorder, and what it means to truly thrive with a complex mental illness. We discuss promising research directions, including GLP-1s, cognitive trajectories, and precision psychiatry. Key Quote: " It's not enough to reduce the bad. We're aiming to increase the good—to help people with bipolar disorder live the full lives they want to live." — Dr. Cara Altimus Breakthrough Discoveries for Thriving with Bipolar Disorder (BD²) is a collaborative initiative building the scientific foundation for better treatments and better lives for people with bipolar disorder. Learn more and get involved at https://www.bipolardiscoveries.org/. Listeners who live with bipolar disorder can learn more about BD2' and their ongoing study described in this episode by visiting bipolardiscoveries.org or sending an email to info@bipolardiscoveries.org.    The study is taking place in partnership with 11 medical institutions across 44 locations in the U.S. and Canada. The medical institutions are: Mass General Brigham (Massachusetts) McLean Hospital (Massachusetts) Johns Hopkins University (Maryland) Mayo Clinic (Minnesota and Arizona) University of California Los Angeles (California) University of California San Diego (California) University of Michigan (Michigan) The University of Texas Health Science Center at Houston (Texas) The Feinstein Institutes for Medical Research (New York) The University of Texas at Austin (Texas) University of Cincinnati/Lindner Center of HOPE (Ohio) Ottawa Hospital Research Institute (Canada)   Listeners can also sign up for the BD2' newsletter, Thrive Updates, at bipolardiscoveries.org and learn more by following on LinkedIn, BlueSky, and X at BD2Discoveries.  Timestamps: 05:31 Understanding Bipolar Disorder: Definitions and Types 14:48 The Role of Genetics in Bipolar Disorder 20:57 Research Funding and Its Impact on Bipolar Disorder 26:51 Stigma Surrounding Bipolar Disorder and Its Effects 32:07 Breaking the Stigma of Mental Illness 36:51 Thriving with Bipolar Disorder 42:12 The Integrated Network: A New Approach to Bipolar Research 47:39 Shifting Perspective From Symptom Reduction to Thriving 53:46 Understanding the Complexities of Bipolar Disorder

Health Secretary Robert F. Kennedy Jr has canceled nearly half a billion dollars in federal funding for future vaccine development.On Today's Show:Michael Osterholm, PhD, MPH, founding director of the Center for Infectious Disease Research and Policy (CIDRAP), member of the Vaccine Integrity Project, and the author, with Mark Olshaker, of the forthcoming book, The Big One: How We Must Prepare for Future Deadly Pandemics (Little, Brown Spark, 2025), talks about RFK, Jr.'s cuts to mRNA vaccine development and what it means for public health and science, plus other vaccine-related news.

Public Health Careers podcast episode with Tim Leshan, MPAIn this episode, Tim Leshan, MPA, Chief External Relations and Advocacy Officer for the Association of Schools and Programs of Public Health, discusses the importance of public health advocacy, the economic impact of public health initiatives, and the need for effective communication with policymakers. He shares insights on building public-private partnerships, navigating challenges in the current political landscape, and the significance of education and storytelling in public health. Tim emphasizes the importance of hope and engagement for young professionals in the field, while also reflecting on his personal journey and career development in public health advocacy.

Today on AirTalk, we take a look at the air quality ahead of the upcoming heatwave; UCLA faces the latest federal funding cuts to its research; what TV shows were cancelled too early?; utilities are slowly moving forward with plans to put power lines underground and what is the weirdest odd job you have ever had? Today on AirTalk: Air quality update and the upcoming heatwave (00:15) UCLA faces funding cuts (10:54) TV shows cancelled too soon (33:48) Plans for buried power lines worry homeowners (51:16) State of US climate change (1:06:24) Weirdest odd jobs (1:32:25) Visit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency!

Alondra Nelson is arguably the most important sociologist of science in America. She isn’t just a brilliant researcher of how race and racism has shaped public health in America, nor just a thoughtful, savvy tech policy maker. She is also someone with a gift for communicating research and ideas on these huge, important matters in […]

As the Trump administration reshapes how federal dollars flow to universities, reform-minded academics are rethinking how to fix the systemic problems on campus without jeopardizing important research.Simon Johnson, professor of entrepreneurship at MIT Sloan School of Management and Nobel Laureate in Economics, joins Oren to unpack why our nation's bloated and bureaucratic universities need reform and how smarter use of federal funding can incentivize it. Plus, the two make sense of how to create new innovation clusters at universities nationwide rather than just at elite coastal institutions.

In this episode, Jessica Levinson unpacks the major legal clash between Harvard University and the Trump administration over a $2.6 billion freeze on federal research funding that impacts vital medical studies. Harvard argues the cuts violate its First Amendment rights and the Administrative Procedures Act, claiming they're being punished for not complying with federal demands related to antisemitism policies. The Trump administration insists it's merely a contract dispute, asserting their right to cut funding if Harvard doesn't align with federal priorities. Jessica highlights that the judge in the case seems skeptical of the Trump administration's stance and notes that the outcome could have sweeping effects on academic freedom and federal funding for universities across the country.Here are three key takeaways you don't want to miss:The Legal Battle Over Federal Funding and Academic Freedom: The episode centers on the case of Harvard University vs. the Trump administration over a $2.6 billion freeze in federal research funding to Harvard. Jessica Levinson explains that this legal clash is significant because it questions the extent of federal power over universities and touches on core issues of academic independence and freedom.Harvard's Arguments: First Amendment and Administrative Procedures Act: Harvard argues that the funding freeze violates its First Amendment rights—claiming it's being punished for not complying with federal demands that affect speech and institutional governance. Additionally, Harvard contends the Trump administration failed to follow the correct legal processes outlined in the Administrative Procedures Act, making the funding cuts arbitrary and lacking proper justification.The Trump Administration's Position and Judicial Skepticism: The Trump administration frames the dispute as a simple breach-of-contract issue, saying grant contracts allow for cancellation when an institution's actions don't align with federal priorities. In court, however, the judge sounded skeptical of the administration's position, questioning whether the funding cut was improperly suppressing speech and whether there was enough evidence to justify such a drastic move.Follow Our Host: @LevinsonJessica

P.M. Edition for July 21. The battle between Harvard University and the Trump administration reached a crescendo today as they met in a federal courtroom in Boston over the government's cancellation of more than $2 billion of research funding. We hear from WSJ higher education reporter Sara Randazzo about the case, and where it goes from here. Plus, as the valuations of chip companies rise, Heard on the Street writer Asa Fitch says investors are ignoring the looming threat of tariffs on chips. And slumping U.S. EV sales mean that battery makers have capacity to spare, so they're turning to a new market: energy-storage systems. WSJ autos reporter Chris Otts tells us what the impact of such a pivot might be. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

At the 2025 ATS International Conference, Joshua Fessel, MD, PhD, ATSF, formerly of the NIH, and Shade Afolabi, MD, a pediatric pulmonologist practicing in Texas, sat down to discuss the extensive ramifications the cuts to the NIH caused researchers, clinicians, and patients. With host Erika Moseson, MD, MA, they explore the effects of losing funding on critical research projects, how patient families have been dealing with pauses on disease research, and how the field can help retain and support early career professionals affected by these policy decisions. Did you miss the ATS 2025 International Conference? Or were you unable to attend some key sessions? Go to conference.thoracic.org/program/conference-highlights/ to purchase your ATS Conference Highlight Package. Be sure to check out the Out of the Blue podcast from the American Journal of Respiratory and Critical Care Medicine, which takes you out of the pages of the Blue Journal and into the minds of the most brilliant researchers in the fields of respiratory, critical care, and sleep medicine. Tune in wherever you listen to podcasts! 

This is the afternoon All Local update for Saturday, July 12, 2025.

This episode features Paige Twenter, Assistant Editor at Becker's Hospital Review, sharing insights on two major developments in healthcare. She discusses the Joint Commission's sweeping reduction of hospital standards and the recent court rulings that reinstated billions in NIH research grant funding, signaling significant changes for academic medicine.

Over the last few months, the Trump administration has directed federal agencies such as the National Institutes of Health and National Science Foundation to cut funding for research with any connection to “diversity,” “equity” or “gender ideology.” The cuts have forced researchers across the country, including in Oregon, to stop their studies or scramble to locate alternative funding.   We’ll hear from three researchers whose federal grants were cancelled: Marguerita Lightfoot is a professor at the OHSU-PSU School of Public Health. Lauren Forrest is an assistant professor of psychology at the University of Oregon. Tala Navab-Daneshmand is an associate professor of environmental engineering at Oregon State University.    They join us to talk about the negative impact the cuts will have on efforts to address health disparities in the U.S.  

255: On today's episode of the Realfoodology Podcast, I sit down with returning guest Dr. Joel Warsh - aka Dr. Joel Gator on Instagram - to talk about his new book Between A Shot and A Hard Place. I've been doing more episodes on vaccines lately, and before you tune out, I just want to say: this is not an anti-vax conversation. It's about asking questions. Dr. Joel is a pediatrician who started digging into the research for his book and was shocked by how little we actually know. We talked about the lack of liability in vaccine development, the censorship around this topic, and how we can create space for real, open dialogue. I hope you'll listen with an open mind. Topics Discussed → Why Dr. Joel wrote Between A Shot and A Hard Place → Vaccine propaganda, censorship, and open dialogue → The 1986 Vaccine Injury Liability Act → Autism, risk factors, and vaccine hesitancy → Informed consent and questioning medical norms Sponsored By: → Timeline | They're offering my audience a 20% discount on all first-time purchases! Use code REALFOODOLOGY at checkout at timeline.com/REALFOODOLOGYGUMMIES → LMNT | Get a free 8-count Sample Pack of LMNT's most popular drink mix flavors with any purchase at drinklmnt.com/realfoodology. → Qualia | Go to qualialife.com/REALFOODOLOGY for up to 50% off your purchase and use code REALFOODOLOGY for an additional 15%.  → MANUKORA | Go to Manukora.com/REALFOODOLOGY to get $25 off the Starter Kit, which comes with an MGO 850+ Manuka Honey jar, 5 honey travel sticks, a wooden spoon, and a guidebook!  → Paleovalley | Save at 15% at paleovalley.com/realfoodology and use code REALFOODOLOGY → Jaspr | Get $400 off with code REALFOODOLOGY and link is jaspr.co/realfoodology Timestamps:  → 00:00:00 - Introduction  → 00:04:10 - “Between A Shot and A Hard Place“ and Vaccine Propaganda  → 00:06:37 - Vaccine Literature and Potential Unknown Risks → 00:09:15 - Censorship of Vaccine Discussions → 00:18:11 - Autism and the Andrew Wakefield Study → 00:22:56 - Vaccine Liability Act → 00:26:13 - Side effects of pharmaceutical interventions → 00:32:16 - Encouraging Critical Thinking in Medicine → 00:34:59 - Rethinking Doctor Training Regarding Vaccines → 00:39:46 - Viewing Vaccines From a Parent's Perspective → 00:43:03 - Navigating Vaccine Hesitancy, Patient Transparency, and Autism Statistics → 00:46:03 - The Impact of Autism on Families → 00:49:51 - Autism in  Unvaccinated Children → 00:54:11 - What Surprised Dr. Joel Most in His Research → 00:59:56 - Modern Health Concerns and Life Expectancies → 01:02:10 - Rising Diagnoses and the Role of Informed Consent → 01:08:18 - Challenges in U.S. Research Funding → 01:12:23 - RFK Jr.'s Involvement → 01:15:53 - HPV and the Gardasil Vaccine → 01:19:59 - Advice for Parents Seeking Vaccine Clarity → 01:29:39 - The Importance of Asking Questions → 01:32:07 - Where to find Dr. Joel Warsh Show Links: → Toxins, Over-Sanitizing + Children's Health | Dr. Joel Warsh Check Out Dr. Joel Warsh: → Between A Shot and A Hard Place → Instagram → X Check Out Courtney:  → LEAVE US A VOICE MESSAGE → Check Out My new FREE Grocery Guide! → @realfoodology → www.realfoodology.com → My Immune Supplement by 2x4 → Air Dr Air Purifier → AquaTru Water Filter → EWG Tap Water Database Produced By: Drake Peterson

Welcome to a preview of the 19th Ask Me Anything (AMA) episode, part of Huberman Lab Premium. If you're an existing Huberman Lab Premium member, you can log in to access the full episode at https://hubermanlab.supercast.com. You can access the transcript here. If you're not a member, you can learn more and join Huberman Lab Premium at https://www.hubermanlab.com/premium. ROKA Wind Down™: https://www.roka.com/huberman Huberman Lab Essentials: https://go.hubermanlab.com/essentials Timestamps 00:00:00 Introduction 00:00:15 The Importance of Light Management for Sleep 00:00:58 Huberman Lab Premium 00:01:33 Research Funding & Matching Donations 00:03:05 Subscription Details & Benefits 00:03:48 Protein Sources 00:05:18 Comparing Whey Protein, Bone Broth, & Collagen 00:10:08 Protein Intake Recommendations 00:14:22 Whey Protein & Skin Health 00:17:42 Conclusion In the full AMA episode, we cover: Creatine & Water Retention Creatine for Brain Health Creatine Use in Teenagers Safety & Effects of Smelling Salts Other Stimulants: Caffeine & Nicotine Prescription Stimulants & Cognitive Enhancers Disclaimer & Disclosures

The Trump administration is waging a ‘wholesale assault on U.S. science’ that threatens the country’s health, economic development, national security and scientific preeminence. That's according to an open letter published by nearly 2,000 doctors, scientists and researchers. William Brangham discussed the letter with Dr. Steven Woolf, one of its authors. PBS News is supported by - https://www.pbs.org/newshour/about/funders

Federal funding from the National Institutes of Health has driven the biomedical research industry in cities across America including Birmingham, Alabama. It's helped support research into life-saving treatments for cancers, strokes and Parkinson's. But, the Trump Administration says the NIH is getting ripped off in how those grants are calculated. We take a look.Related episodes:The gutting of USAID (Apple / Spotify)A 'Fork in the Road' for federal employees (Apple / Spotify)For sponsor-free episodes of The Indicator from Planet Money, subscribe to Planet Money+ via Apple Podcasts or at plus.npr.org.Fact-checking by Sierra Juarez. Music by Drop Electric. Find us: TikTok, Instagram, Facebook, Newsletter. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Guests: Xavier Becerra, Sherrilyn Ifill, Sen. Mark Kelly, Anthony RomeroTonight: the untold cost of three days of Trump. Then, Sherrilyn Ifill on the Trump executive order deemed "blatantly unconstitutional" by a federal judge. Plus, separating propaganda from reality as Trump TV rides along for ICE raids. And a scathing rebuke from two Republican Senators as the Hegseth nomination moves toward a vote. Want more of Chris? Download and subscribe to his podcast, “Why Is This Happening? The Chris Hayes podcast” wherever you get your podcasts.